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Abstract We evaluated 132 galactosemia patients for the 
Q188R (glutamine-188 to arginine) mutation in the hu- 
man galactose-1-phosphate uridyltransferase (GALT) gene 
and for GALT activity in their hemolysates by a sensitive 
radioisotopic method. In those without any detectable 
GALT activity (GG), the Q 188R mutation constituted 67% 
of the alleles. In patients with detectable GALT activity 
(GV), only 16% of the alleles were accounted for by 
Q188R. In all patients who were homozygous for the 
Q188R mutation, no erythrocyte GALT activity could be 
demonstrated. There was an extensive variation in the 
amount of detectable GALT activity ranging from 0.1% to 
5% of the normal values among the GV patients. There 
was a difference in the frequency of Q188R mutation in 
the GALT alleles among patients belonging to different 
racial and ethnic groups. In Caucasian and Hispanic pa- 
tients, the frequency was not far different (64% and 58%, 
respectively). On the other hand, only 12% of the GALT 
alleles with Q188R were found in African-American pa- 
tients. 
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Introduction 
Galactosemia (McKusick no. 230400) is an inborn error 
of  galactose metabolism due to galactose- 1-phosphate uri- 
dyltransferase (GALT) enzyme deficiency (Segal 1989). 
Clinical and biochemical heterogeneity among galactos- 
emia patients was described in the early 1960s (Hsia and 
Walker 1961; Ng et al. 1964). An extensive survey of the 
clinical and biochemical findings in 350 cases was report- 
ed (Waggoner et al. 1990). In 1965 some African-American 
patients were found to have the capacity, albeit small, to 
metabolize galactose (Segal et al. 1965). Besides the Afri- 
can-American variant, others such as the isolated cases of 
the Rennes (Schapira and Kaplan 1969), Indiana (Chacko 
et al. 1971) and Chicago I (Chacko et al. 1977) variants 
were described. A recent study of 358 patients suggested 
that there was a correlation between the severity of the clin- 
ical presentation and the degree of enzyme deficiency and 
that this also was reflected in the erythrocyte galactose-1- 
phosphate (Gal- l -P)  and uridine diphosphate galactose 
(UDPGal) levels (Ng et al. 1991). 
The cloning and characterization of the cDNA encoding 
human galactose-1-phosphate uridyltransferase by Rei- 
chardt and Berg (1988) has provided a means of studying 
the nature of  the gene defect in galactosemia and its clin- 
ical expression. The entire gene for GALT was sequenced 
(Leslie et al. 1992), and a number of mutations among 
galactosemia patients have been uncovered (Reichardt 
1992). The most common mutation among galactosemia 
patients appears to be the Q188R (glutamine-188 to argi- 
nine) in exon 6 (Reichardt et al. 1991; Elsas et al. 1993). 
It has recently been suggested that there was a higher fre- 
quency of Q188R homozygosity in patients with a poor 
outcome (Elsas et al. 1992). 
This study presents biochemical findings and Q188R 
mutation analysis for 132 patients. 
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Racial and ethnic 
background: 
Regional distribution: 
79 females, 53 males 
NBS (70), clinical (47), siblings (15) 
0-5 years (54), 6 17 years (36), 
> 17 years (42) 
Caucasian (106), African American (12) 
Hispanic (9), African American-Caucasian 
( 1 ), African American-Hispanic ( 1 ), 
Hispanic-Native American (1), Native 
American (2) 
West (68), Midwest (34), East (17), South 
(10), Canada (3) 
Materials and methods 
Patients 
The total number of patients studied was 132 and the demographic 
data on their samples is shown in Table 1. All had erythrocyte 
galactose-l-phosphate uridyltransferase (GALT) assays and DNA 
Q188R mutation analysis on blood samples collected from filter 
paper spots. In addition, a number of patients had uridine diphos- 
phate glucose (UDPGlc) and uridine diphosphate galactose mea- 
surements made on their erythrocytes by an enzyme coupling method. 
Preparation of blood samples 
For GALT assay and UDPGIc and UDPGal measurements, blood 
was washed three times with physiological saline (0.9 g% NaCI) 
after removal of plasma and buffy coat. Red blood cells were im- 
mediately frozen until analysis. For DNA analysis, whole blood 
was received in either sodium heparinized or EDTA anticoagulant 
tubes. Blood was applied onto filter paper spots, air dried, and then 
stored frozen until analysis. 
GALT assay 
The multiple point radioisotopic assay for GALT activity has been 
described previously (Ng et al. 1991), and the details of the assay 
will be reported in a future publication (W. G. Ng, in preparation). 
In essence, a 50% hemolysate was prepared from 0.2-0.3 ml of 
frozen red blood cells by addition of an equal volume of distilled 
water. Then 0.2-0.5 ml of the 50% hemolysate was dialyzed 
against I 1 of GEM buffer, which was made up of 0.1 M glycine, 
0.001 M EDTA, and 0.003 M [3-mercaptoethanol, pH 8.0 at 4~ 
overnight. Then 20lal of dialyzed hemolysate was incubated with 
100 lttM of highly labeled t4C-Gal- I -P (sp. act. of 5 mCi/mM) from 
NEN (Dupont, Mass.) and 80 taM UDPGIc in a glycine-dithiothre- 
itol buffer, pH 8.7 with a total volume of 100 gl for 10, 30, and 60 
min. At the end of each incubation period, 10 lal aliquots were 
spotted on DEAE-81 paper strips and chromatographed in 0.05 M 
LiCI. Radioactivities in sections corresponding to UDPhexose 
(UDPGal) and Gal- l-P were determined by liquid scintillation 
counting. Galactose-l-phosphate uridyltransferase (GALT) activ- 
ity was expressed as [,tmol/h/g Hb. The sensitivity of the assay is at 
about 0.1% of normal activity. For a blood sample from normal in- 
dividuals, a 1% hemolysate should be used because the assay is 
suitable only for low GALT activity; higher activity would result 
in rapid disappearance of the substrates. 
Erythrocyte UDPGlc and UDPGal measurements 
The levels of these nucleotide sugars were determined in an aque- 
ous boiled extract by a modification of the procedure originally de- 
scribed by Ng et al. (1989). The modifications included correction 
of reagent blanks, which might give fluorescent readings, and 
omission of cysteine, which was found to be unnecessary. The 
UDPGIc dehydrogenase supplied from Sigma (U5500) and 
Boehringer Mannheim was used at 0.00125 U per incubation. 
Polymerase chain reaction (PCR) assay 
A l-mm 2 sample from a blood spot or 0.1 lag genomic DNA was 
amplified in a 100 gl reaction with 0.5 Iag of each primer, sense: 
6-5", CTGTTTCCACAGGGTGTGG and anti-sense: 6-3", GCT- 
GGCTCAGACTCAGCC, synthesized on a Beckman Oligo 1000; 
(Fullerton, Calif.); amplifying all of exon 6 in the nomenclature of 
Leslie et al. (1992) as follows: after an initial denaturation at 97~ 
for 5 min, primers were annealed/or 10 s at 50~ and 1.5 U Taq 
DNA polymerase (Promega, Madison, Wis.) were added and the 
products were then extended for 5 min at 72~ Next 40 cycles 
consisting of denaturation for 1 rain at 94 ~ C, annealing for 10 s at 
57~ and extension for 40 s at 72~ were performed in an Eft- 
comp Twinblock (San Diego, Calif.). Finally, the PCR products 
were blunted for 5 rain at 72~ Successful amplification was ver- 
ified on a 4% NuSieve 3:1 analytical gel (FMC, Rockland, Me.). 
Hpall assay of Q 188R 
A 20-lal sample of the PCR reaction was mixed with 2 lal of buffer 
A (Promega), and 2 U of Hpall (Promega) were added. PCR prod- 
ucts were digested overnight at 37~ and then analyzed on a 4% 
NuSieve 3:1 agarose gel (FMC). The size of the PCR product was 
185 bp. After the digestion, Q188R mutation resulted in two frag- 
ments, 135 bp and 50 bp. 
Results 
Pat ien ts  w i th  g a l a c t o s e m i a  h a v e  b e e n  c l a s s i f i ed  into  t w o  
groups :  G G  (pa t ien ts  w i t h o u t  de t ec t ab l e  e r y t h r o c y t e  
G A L T  ac t iv i ty )  and G V  (pat ients  wi th  de t ec t ab l e  e ry-  
t h rocy te  G A L T  ac t iv i ty )  based  on the p r e s e n c e  and ab-  
s ence  o f  de t ec t ab l e  G A L T  ac t iv i ty  in e r y t h r o c y t e s  as de-  
t e r m i n e d  by the m u l t i p o i n t  r a d i o i s o t o p i c  assay,  (Ng  et al. 
1991). E r y t h r o c y t e  G A L T  ac t iv i ty  in 132 pa t ien ts  in this 
s tudy  was  c o m p a r e d  wi th  the resul t s  ob t a ined  by Q 1 8 8 R  
muta t i on  analys is .  T h e  f ind ings  are  s u m m a r i z e d  in Tab le  
2. T h e r e  w e r e  113 pa t ien ts  in the G G  g r o u p  and 19 pa-  
t ients  in G V  group .  In the G G  group ,  56 pa t ien ts  w e r e  
h o m o z y g o u s ,  40 pa t ien ts  h e t e r o z y o u s ,  and 17 pa t ien ts  
n e g a t i v e  for  the  Q I 8 8 R  muta t ion .  Th i s  cons t i t u t ed  6 7 %  
o f  the G A L T  a l le les  w i th  the  Q 188R muta t ion .  In the G V  
group,  6 patients were  he te rozygous  and 13 patients were  
n e g a t i v e  fo r  the  Q I 8 8 R  muta t ion .  Thus ,  in this g roup ,  
on ly  16% o f  the  G A L T  a l le les  had  the Q 1 8 8 R  muta t ion .  
T a k e n  as a w h o l e  ( G G  and G V ) ,  56 pa t ien ts  w e r e  ho-  
m o z y g o u s  for  the  Q I 8 8 R  muta t ion ,  46 h e t e r o z y g o u s ,  
and 30 d id  not  exh ib i t  the muta t ion .  Th i s  y i e lded  6 0 %  
(158 /264)  o f  G A L T  a l le les  wi th  Q 1 8 8 R  muta t ion .  An  in- 
t e res t ing  o b s e r v a t i o n  was  that  all pa t ien ts  h o m o z y g o u s  
fo r  the Q 1 8 8 R  m u t a t i o n  had  no de t ec t ab l e  G A L T  ac t iv i ty  
and none  o f  the  pa t ien ts  wi th  d e t e c t a b l e  G A L T  ac t iv i ty  
w e r e  h o m o z y g o u s  for  the Q 1 8 8 R  muta t ion .  
F igure  1 shows  the spec t rum o f  e ry th rocy te  G A L T  ac- 
t iv i ty  de tec ted  for  19 G V  pat ients :  12 were  Caucas ians ,  4 
w e r e  Af r i can  A m e r i c a n s ,  and 3 were  Na t ive  A m e r i c a n s .  
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Table 2 Correlation of Q188R mutation with galactose-l-phos- 
phate uridyltransferase (GALT) activity 
Groupa +/+ +/- - / -  % + alleles 
GG(I13) 56 40 17 67 
GV (19) 0 6 13 16 
56 46 30 60 
a GG, patients without any detectable GALT activity; GV, patients 
with detectable GALT activity; affected sibs are included 
Table 3 Q188R analysis of galactosemia patients according to 
different racial and ethnic background. Affected sibs are excluded 
Group +/+ +/- - / -  % + alleles 
Caucasian 44 34 17 64 
African American 1 2 9 12 
Hispanic 2 3 1 58 
African American Hispanic 1 - 
African American-Caucasian 1 - 
Hispanic-Native American 1 - 
Native American 1 - 
1.1 ee 
1.0 - 
0 .9  - 
0 , 8 -  
"I" 
0 . 7  -- 
0 . 6  - 
< 0 . 5 -  
I-- 
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GV Patients 
Fig.1 Spectrum of erythrocyte GALT activity found among 19 
GV patients 
Of these, 16 patients were identified by newborn screen- 
ing programs and 3 were initially suspected based on clin- 
ical grounds. Of the 16 patients identified by newborn 
screening, 1 exhibited hepatomegaly and 1, jaundice. In 
these 2 patients, who were both African Americans, the 
GALT activity was low: 0.02 and 0.08 units, respectively 
(normal > 20 units). The remaining 14 were asympto- 
matic, Two of these patients were Native American sib- 
47 41 29 58 
lings with erythrocyte GALT activities of 0.7 and 0.9 
units. One other patient, of Native American and Hispanic 
descent, also exhibited substantial residual activity equal 
to 1.1 units. Among the three patients with detectable 
GALT activity identified on the basis of clinical suspi- 
cion, two females had classical clinical onset in the neo- 
natal period. Both of them are now of adult age and con- 
tinue to exhibit normal ovarian function. The third patient, 
now a 12-year-old male, was found to have lenticular 
cataracts as a child but was not suspected of having galac- 
tosemia until his younger brother was diagnosed on new- 
born galactosemia screening. All of the three patients 
were Caucasians, and their GALT activities were 0.02, 
0.03, and 0.14 units, respectively. 
Table 3 summarizes the results of Q188R mutation 
analysis on galactosemia patients according to their racial 
and ethnic background. Data on only index cases were in- 
cluded, while data from affected sibling were excluded 
from the table. In the Caucasian group, mostly of Euro- 
pean origin, the percentage of alleles with Q188R muta- 
tion was 64%, and that for the small number of samples in 
the Hispanic group was similar (58%). Most of the His- 
panic patients came from Mexico and can be classified 
into the Caucasian group. On the other hand, the fre- 
quency of the Q188R mutation in African Americans was 
considerably lower (12%). Excluding affected siblings, 
about 58% of the GALT alleles in the 117 patients studied 
had the Q188R mutation. 
UDPGlc and UDPGal levels in the erythrocytes were 
measured by an enzymatic method in 72 of the 132 galac- 
tosemic patients in this study (64 GG and 8 GV). The lev- 
els of UDPGlc in GG, GV, and the controls are similar: 
normals (40) : 21.3 + 3.9, GG (64) : 19 + 4.5, and GV (8): 
18.4 + 2.1 ~tmol/100 g Hb. However, for UDPGal, all 64 
GG patients had lower values than the controls and nor- 
mal values in all 8 GV patients: normals (40): 8.4 + 1.0, 
GG (64): 2.5 + 0.8, and GV (8) 8.2 + 0.8 umol/100 g Hb. 
The absolute values by our enzymatic method were higher 
than those found by HPLC analysis (Palmieri et al. 1991) 
including our work (Xu et al. 1993). Nevertheless, the 
findings of lower values of UDPGal in GG and normal 




The successful cloning of the cDNA for human galac- 
tose-l-phosphate uridyltransferase was accomplished by 
Reichardt and Berg (1988). Subsequently, the sequence of 
the cDNA was revised by Flach et al. (1990), and the en- 
tire gene for the enzyme has been sequenced by Leslie et 
al. (1992). 
A number of  mutations in the GALT gene have been 
identified, and the most common of these among galac- 
tosemia patients is Q I88R in exon 6 (Reichardt et al. 
1991; Elsas et al. 1993). Our present study of 132 patients 
confirms these findings. Altogether 60% of the GALT al- 
leles have this mutation (and 58% of 117 patients studied 
when affected siblings were excluded), which is compara- 
ble to the findings of Elsas et al. (1993) of 66% on 52 pa- 
tients. This contrasts with what was initially reported by 
Reichardt et al. (1991) of an overall frequency of only 
26%, which may have been due to a difference in the sam- 
pling procedure or a different study population. 
However, the frequency of Q188R mutation among 
galactosemia patients is different if the presence or ab- 
sence of GALT activity is taken into account. Previously, 
we had reported extensive biochemical heterogeneity 
among galactosemia patients identified either by newborn 
screenig or clinical recognition (Ng et al. 1991). We have 
arbitrarily classified patients without detectable GALT ac- 
tivity as GG and those with detectable GALT activity 
(> 0.1% of normal controls) as GV. Of the 132 patients 
who had DNA Q188R analysis, 113 were found to be GG 
and 19 GV. Of the GG group, a frequency of 67% of the 
GALT alleles for this mutation was obtained. This is in 
contrast to GV group with only 16%. Of the latter group, 
not a single individual was a homozygote for the muta- 
tion. On the basis of this data, our preliminary conclusion 
is that patients homozygous for Q188R are devoid of 
GALT activity as measured by our multipoint assay. This 
finding indicates the importance of proper classification 
of galactosemia patients before results of either molecular 
studies or biochemical studies can be compared. 
We have found that the frequency of Q I88R differs 
among different racial and ethnic groups of patients. In 
the Caucasian group, of 95 patients, 64% of the alleles 
had this mutation. On the other hand, the frequency of 
Q I88R mutation in the alleles among 12 African Ameri- 
can patients was considerably lower (12%). This is simi- 
lar to the figure of 12.5% reported by Elsas et al. (1993) in 
a study of 4 patients. 
The significantly lower frequency of Q I88R in 
African-American galactosemia patients is noteworthy. It 
suggests that the African-American variant named previ- 
ously as "Negro" variant of galactosemia (Segal 1969) is 
genetically distinct from the disease found in Caucasian 
patients. In fact, Reichardt et al. (1992) had proposed that 
the FI71S mutation and S135L protein polymorphism 
were the result of racial admixture in African-American 
patients. The frequency of Q l88R we observed in our 
study of African-American patients (12%) approaches the 
frequency expected for Caucasian admixture: 0.64 • 0.25 
= 0.16 (Chakraborty et al. 1992). It also is noteworthy that 
Q I88R is very rare in other racial groups such as Native 
American (Table 2), East Indian, Japanese, and Pakistani 
(J.K.V. Reichardt et al., unpublished). Thus, the molecular 
changes in galactosemia though present in all racial 
groups studied to date appear to vary considerably. 
In this study of 132 patients, 19 were found to have de- 
tectable GALT activity, ranging from 0.02 to 1.1 units 
(normal controls of  > 20 units). Since most of them were 
identified by newborn screening, it is not known how 
many would have had clinical problems if untreated. 
Cataracts was found in one patient in this study. Females 
including two adults with detectable GALT activity ap- 
pear to maintain normal ovarian function (Kaufman et al. 
1988). Whether the presence of minute GALT activity and 
normal levels of UDPGal in GV patients would preserve 
the ovarian function remains to be studied. A clinical cor- 
relation of cognitive, neurologic and ovarian outcome 
with the Q188R mutation in patients with absence of 
GALT activity is being reported (Kaufman et al. 1994). 
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